ArticleChemistry & biodiversity2026
Novel Isoniazid-Based 1,3,4-Oxadiazole-Fatty Acid Hybrids: Synthesis, In Vitro Biological Activity and In Silico ADME/Tox Predictions.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer and multidrug-resistant (MDR) bacterial infections are pressing global health concerns that demand continuous studies on new bioactive compounds. With a view to create new bioactives, the present study reports on the design and synthesis of novel fatty acid derivatives containing oxadiazole moiety and isoniazid in a molecular entity. The structures of the synthesized compounds were confirmed through nuclear magnetic resonance (NMR), infrared (IR) and mass spectrometry. Anticancer screening revealed that compounds 7b and 7e demonstrated notable cytotoxic activity, particularly against the B16-F10 cell line. Compound 7b exhibited the most potent activity with an IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.